Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-003 (Adept Biopharmaceutical)
- Development stage
- Preclinical
- Lead developer
- Anpu Biomedical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AT-003 is a preclinical-stage bispecific antibody candidate developed by Adept Biopharmaceutical for the treatment of various solid tumors. Functioning within the immuno-oncology space, the molecule is engineered to simultaneously target two distinct antigens to enhance anti-tumor immune responses. Although the specific binding targets of AT-003 remain undisclosed by the company, the asset represents a key component of Adept's strategy to develop multi-specific biologics that overcome the limitations of traditional monoclonal antibodies in the tumor microenvironment.
Beyond the preview
Go deeper on AT-003 (Adept Biopharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-003 (Adept Biopharmaceutical).